U.S. Department of Health and Human Services (HHS)

Parent: UC Comment Letters

eScholarship stats: History by Item for July through October, 2026

ItemTitleTotal requests2026-102026-092026-082026-07
9st228b4UC Response to NIH Pause on New Submissions to the NIH Human Embryonic Stem Cell Registry and Request for Information on Reducing Reliance on Human Embryonic Stem Cells in NIH-Supported Research (NOT-OD-26-031)12630879
442553qvUC Comments on NIH's Request for Information on Proposed Changes to Reporting Outcomes from NIH Peer Review7777
9vw6z5h0UC Comments on NIH/OLAW's RFI on Update to NOT-OD-05-034 Guidance on Prompt Reporting of Noncompliances to OLAW (NOT-OD-23-063)7134289
7br0n9jbUC Comments in Response to NOT-OD-23-034, "Request for Information (RFI) on Proposed Simplified Review Framework for NIH Research Project Grant Application"5435163
9vd827xqUC Comments on Draft OHRP Guidance on Use of a Single Institutional Review Board for Cooperative Research (Docket ID Number HHS-OASH-2022-0011, July 1, 2022)461333
99n0x1kkUC Comments on NIH/OLAW's RFI on Proposed Guidance to Assured Insitutions on Cephalopod Care and Use (NOT-OD-23-176)4314218
0gr9367zUC Comments in Response to the NIH Request for Information: Developing Consent Language for Future Use of Data and Biospecimens (NOT-OD-21-131)422418
19t30344University of California Response to NIH Request for Information on Maximizing Research Funds by Limiting Allowable Publishing Costs (NOT-OD-25-138)4121137
9sn6m48bUC Comments on FDA's Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry; Availability (Docket No. FDA-2021-D-1214, December 9, 2021)401525
3591b3jzUC Comments on FDA Guidance Document: Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices (FDA-2021-D-0368)3712205
4rw9g2k6University of California Response to NIH Request for Information on Draft NIHControlled-Access Data Policy and Proposed Revisions to NIH Genomic Data Sharing Policy(NOT-OD-26-023)3720143
7v11n0rmUC Comments on FDA Docket No. FDA-2019-N-2175 for “Institutional Review Boards; Cooperative Research.” (September 28, 2022)361719
06g5v1tpUC Comments in Response to 2024-16496 (89 FR 60985) & 2024-22146 (89 FR 78835), End-Use and End-User Based Export Controls, Including U.S. Persons Activities Controls: Military and Intelligence End Use and End Users (July 29, 2024), RIN 0694-AJ43351520
8m65c5h9UC Comments in Response to NOT-OD-21-018, “Request for Information (RFI):Inviting Comments and Suggestions on the NIH-Wide Strategic Plan for COVID-19 Research”351124
3pm6d220UC Response to Comment Request on NIH Electronic Application System for NIH Certificates of Confidentiality (CoC) [90 FR 30652]3413147
637846c7UC Comments in Response to NIH's RFI on the NIH Draft Public Access Policy341024
7sz8s1zcUC Comments in Response to the Request for Information on Proposed Updates and Long-Term Considerations for the NIH Genomic Data Sharing Policy (NOT-OD-22-029)331518
6bk2s9gfUC Comments NIH's RFI on Developing Consent Language for Research Using Digital Health Technologies (NOT-OD-24-002)3217105
8nj635p3UC Comments in Response to the NIH Request for Public Comments on DRAFT Supplemental Information to the NIH Policy for Data Management and Sharing: Protecting Privacy When Sharing Human Research Participant Data (NOT-OD-22-131)321715
28j9736pUC Request for Extension to Comment Period: Docket No. FDA-2019-N-2175 for “Institutional Review Boards; Cooperative Research.” (September 28, 2022)311615
0r54j9xvUC Comments in Response to NOT-AT-22-026, “Request for Information (RFI): Investigators’ Interests in and Barriers to Research Studies on the Health Effects of Cannabis and its Constituents”301713
5wd6c2xgUC Comments in Response to NIH/OLAW's RFI on Clarification of Animal Activities Exempt from the PHS Policy Requirements for IACUC Review (NOT-OD-23-119)301218
9h75q200UC Comments on Docket No. FDA-2021-N-0286 for “Protection of Human Subjects and Institutional Review Boards” (September 28, 2022)301317
2ng1337vUC Response to HHS Notice of Committee Establishment, Notice of Intent To Convene, and Call for Nominations for the NIH Human Fetal Tissue Research Ethics Advisory Board for Fiscal Year 2020291910
6vx692vqUC Comments on Certificates of Confidentiality; Draft Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff: Availability (FDA-2019-D-3592)291316
0p60d992UC Comments on FDA Final Order regarding Designating Additions to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Acton [FDA-2008-N-0567-0055]271017
5ng1c3d5UC Comments on NIH's Framework for Discussion, dates June 2024, Seeking Input on Reforming the NIH261313
5t52r4mgUC Comments in Response to NOT-OD-26-112 "Request for Comment: Draft NIH Biosafety Policy for Research Involving Biohazards"2525
4p55d0x9UC Comments on the FDA-NIH Resource on Terminology for Clinical Research241212
8z99q8c0UC Request to FDA to Extend Comment Period for Docket No. FDA-2021-N-0286 for “Protection of Human Subjects and Institutional Review Boards” (September 28, 2022)241113
93x6z1b4UC Comments in Response to NOT-OD-23-091, "Request for Information on the NIH Plan to Enhance Public Access to the Results of NIH-Supported Research"241167
9mf9j9bqUC Comments in Response to FDA's Proposed Guidance for Sponsors, Investigators,and Institutional Review Boards on Key Information and Facilitating Understanding in Informed Consent (Docket Number: FDA-2022-D-2997)24816
4fb874mtUC Comments in Response to the HHS Regulations RFI, “Request for Information and Comments on the 2005 Public Health Service Policies on Research Misconduct”21129
5wz509zrUC Comments in Response to NOT-OD-20-013, “Request for Public Comments on a DRAFT NIH Policy for Data Management and Sharing and Supplemental DRAFT Guidance”20119
3rs8v26wUC Letter Regarding Gender Diversity and Inclusion on the OHRP IRB Registration Form19613
2db6h4gdUC Comments in Response to Request for Information (RFI) on Flexibilities for Streamlining IACUC Review of Protocols and Significant Changes (NOT-OD-23-152)17107
5dr3q55jUC Comments on Draft NIH Policy on Sharing Summary Level Study Results with Clinical Research Participants (NOT-OD-26-113)99

Note: Due to the evolving nature of web traffic, the data presented here should be considered approximate and subject to revision. Learn more.